NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $69,008 | $1,121,847 | $2,378,967 | $22,857,988 |
| - Cash | $68,263 | $2,141,445 | $3,214,005 | $3,523,632 |
| + Debt | $3,882 | $133,872 | $38,289 | $112,455 |
| Enterprise Value | $4,627 | -$885,726 | -$796,749 | $19,446,811 |
| Revenue | $0 | $4,486 | -$10,697 | $88,026 |
| % Growth | -100% | 141.9% | -112.2% | – |
| Gross Profit | $0 | $4,486 | -$248,800 | $41,594 |
| % Margin | – | 100% | 2,325.8% | 47.3% |
| EBITDA | -$373,453 | -$344,250 | -$51,230 | -$2,057,531 |
| % Margin | – | -7,674.2% | 478.9% | -2,337.4% |
| Net Income | -$162,257 | -$1,465,694 | -$2,507,317 | -$2,331,541 |
| % Margin | – | -32,674% | 23,438.9% | -2,648.7% |
| EPS Diluted | -4.46 | -17.62 | -30.38 | -30.68 |
| % Growth | 74.7% | 42% | 1% | – |
| Operating Cash Flow | -$52,669 | -$72,854 | -$1,102,805 | -$973,093 |
| Capital Expenditures | -$48 | -$164 | -$45,830 | -$29,932 |
| Free Cash Flow | -$52,717 | -$73,018 | -$1,148,635 | -$1,003,025 |